Sasha Stafford:
Creating Novel Drug Delivery and Vaccine Technologies
An entrepreneur and consultant, Sasha brings over 30 years of professional experience in industry and academia to the conversation. With 15 years at The Wyss Institute at Harvard University, Sasha has innovated new materials and translated drug delivery and vaccine technologies towards patients use. These materials have made their way into multiple technologies, as evidenced by the Highlighted Work below.
Highlighted Work
Sasha Stafford
A Legacy of Innovation in Drug Delivery
Sasha is the primary inventor of biodegradable click alginate hydrogels, a transformative "plug-and-play" technology. This platform enables the localized, sustained delivery of a vast array of therapeutics—from small molecules and proteins to intact liposomes—without requiring complex secondary interactions. His work is currently at the forefront of global health, with his materials integrated into Gate’s Malaria vaccine development and Phase I clinical trials for multi-component melanoma vaccines.
Translational Leadership & Industry Impact
A veteran of both academia and the private sector, Sasha has a proven track record of moving technologies from the bench to the bedside. His career includes pivotal roles at Genzyme, Arriva Pharmaceuticals, and Elan Pharmaceuticals, where he contributed to the FDA approval of major therapies like PRIALT® and TYSABRI® .
Beyond his inventions, he is a prolific contributor to the scientific community, with a robust publication record in journals such as Nature Materials, PNAS, and Nature Communications, focusing on immune-responsive scaffolds and regenerative medicine
Let's Build Something Exceptional Together
Whether you're looking for a lead product designer or want to discuss a new translational strategy, I'm always open to high-impact collaborations.
Sasha is a distinguished scientist and innovator at the Wyss Institute at Harvard University, where he serves as a Senior Staff Scientist on the Advanced Technology Team. With a career spanning over 25 years, Sasha bridges the gap between foundational chemistry and clinical-stage pharmaceutical development, specializing in the creation of sophisticated drug delivery systems.